Having trouble viewing the email? View it here.

A Week in Review
Sign up for this newsletter »Read more at Oncologystat.com »October 6, 2009 | Issue 89


Capecitabine Information
Learn about Effective Oral Chemo Therapy For Breast & Colon Cancer.
www.xeloda.com


Scan of the Week
Perineural Invasion Confers Worse Outcome in Colorectal Cancer
J Clin Oncol, 2009 Sept 8, C Liebig, et al
In this retrospective study, PNI-positive status was a predictor of reduced survival in patients with colorectal cancer.
Weekly Journal ScansMore »
Combined Liver Surgery and RFA for Liver Metastases From Endocrine Tumors
Eur J Surg Oncol, 2009 Oct 1, D Elias, et al
Use of a 1-step approach in patients with 23 liver metastases (median) permitted upgraded therapy and yielded an improved prognosis.
Induction With High-Dose vs Standard-Dose Daunorubicin in AML
N Engl J Med, 2009 Sept 24, HF Fernandez, et al
EXPERT COMMENTARY
Phase III study showed induction with high-dose daunorubicin significantly improved complete remission and survival rates.
PET Interpretation in DLBCL Is Only Moderately Consistent
Blood, 2009 Sept 18, SJ Horning, et al
Scoring of interim PET scans by nuclear medicine experts showed only moderate consistency (16% to 34% range for PET-positive scans).
Normal Marrow Plasma Cells at MM Diagnosis Signify Better Prognosis
Blood, 2009 Sept 15, B Paiva, et al
Detection of >5% residual normal plasma cells corresponded with higher response rates and longer PFS and OS.
Cost Effectiveness of CT Screening in Lung Cancer
Br J Cancer, 2009 Sept 15, AW Castleberry, et al
The cost per 5-year survivor was lower with CT screening than with the symptom-detected approach, especially after age 60.
Carpal Tunnel Syndrome Associated With Anastrozole
J Clin Oncol, 2009 Sept 14, I Sestak , et al
Increased incidence of carpal tunnel syndrome with anastrozole has little impact on the risk-to-benefit ratio in women with breast cancer.
Circulating Tumor Cell Counts Predict Breast Cancer Treatment Outcomes
J Clin Oncol, 2009 Sept 14, MC Liu, et al
A threshold of ≥5 CTCs per 7.5 mL of blood was predictive of treatment outcome in stage IV breast cancer.
Bevacizumab Appears Safe for NSCLC With Brain Metastases
J Clin Oncol, 2009 Sept 8, MA Socinski , et al
Bevacizumab with chemotherapy appears safe and does not increase the risk of CNS hemorrhage.
Fracture Risk With Single-Fraction IG-IMRT to Spinal Metastases
J Clin Oncol, 2009 Sept 8, PS Rose, et al
Factors linked with increased fracture risk after single-dose image-guided intensity modulated RT of spinal metastasis are identified.
Biochemical Recurrence After Prostatectomy for Small-Volume or 'Insignificant' Tumors Free Full-Text PDF
Urol Oncol, 2009 Sept 1, IM van Oort, et al
The 5-year risk of biochemical recurrence was 10% for patients with small-volume or 'insignificant' tumors treated surgically.
The Latest Evidence Regarding Erythropoiesis-Stimulating Agents
Oncologist, 2009 Sept 1, M Aapro, et al
Recent clinical trials and a Cochrane meta-analysis focusing on the effect of ESAs on survival in chemo-treated patients are summarized.
Weekly Review ArticlesMore »
Workup and Staging of Locally Advanced Breast Cancer Free Full-Text PDF
Semin Radiat Oncol, 2009 Oct 1, GJ Whitman , et al
This article reviews work-up and staging in patients with locally advanced breast cancer, including the use of PET, CT, and MRI.
Postmastectomy Radiation Therapy for Locally Advanced Breast Cancer Free Full-Text PDF
Semin Radiat Oncol, 2009 Oct 1, R Jagsi, et al
Clinical trial data and current guidelines support the use of postmastectomy RT in patients with locally advanced disease.

ECCO/ESMO 2009
Conference news plus interviews with ECCO/ESMO officers.



Advertisement.
CANCER POLICY FORUM

Get behind-the-headline perspectives on the politics of cancer.

VISIT SITE
WHEN THE SMOKE CLEARS
Experts discuss the true clinical implications of watershed developments in oncology research.

VISIT SITE
RELATED WEBSITES
These websites offer more information on a variety of oncology-related topics.

VISIT SITE
VIDEOS
Watch video interviews with leading cancer experts.

VISIT SITE
Elsevier Inc. Home | Site Map | Cancer Types | About OncologySTAT | Privacy Policy | Terms of Use | Contact Us | Advertise

You are currently subscribed as %%email%% | Unsubscribe | Update Your Profile
Was this email forwarded to you? Sign-up for your own free subscription.
Copyright © 2012, Elsevier Inc. All rights reserved.
Elsevier Inc., 1600 John F. Kennedy Boulevard, Suite 1800.
Philadelphia, PA 19103-2899, USA